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Mesoporous silica microparticles were prepared, loaded with the
dye safranin O (M-Saf) or with the drug budesonide (M-Bud)
and capped by the grafting of a bulky azo derivative. Cargo
release from M-Saf at different pH values (mimicking those
found in the gastrointestinal tract) in the absence or presence
of sodium dithionite (a reducing agent mimicking azoreductase
enzyme present in the colon) was tested. Negligible safranin O
release was observed at pH 6.8 and 4.5, whereas a moderate
delivery at pH 1.2 was noted and attributed to the hydrolysis
of the urea bond that linked the azo derivative onto the
external surface of the inorganic scaffold. Moreover, a marked
release was observed when sodium dithionite was present and
was ascribed to the rupture of the azo bond in the molecular
gate. Budesonide release from M-Bud in the presence of
sodium dithionite was also assessed by ultraviolet-visible
spectroscopy and high performance liquid chromatography
measurements. In addition, preliminary in vivo experiments
rsos
2with M-Saf carried out in mice indicated that the chemical integrity of the microparticles remained
unaltered in the stomach and the small intestine, and safranin O seemed to be released in the colon..royalsocietypublishing.org
R.Soc.open
sci.5:1808731. Introduction
Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions of the colon and
small intestine with alternate periods of relapse and remission [1,2]. Typical clinical symptoms of
IBD are abdominal pain, diarrhoea, tenesmus and rectal bleeding, caused by ulcerative proctitis or
proctosigmoiditis [3]. IBD is so widespread that it is believed that up to 1% of the population can
be affected. Ulcerative colitis (UC) and Crohn’s disease (CD) are the most common types of IBD
[4,5]. UC affects only the colon and the rectum, whereas Crohn’s can affect any part of the
digestive tract. UC is a disease that causes inflammation and sores (ulcers) in the lining of the
large intestine. It usually affects the lower section (sigmoid colon) and the rectum, but it can affect
the entire colon.
UC can be treated with a large number of drugs, including 5-ASA derivatives such as sulfasalazine
and mesalazine [6,7]. Immunosuppressive medications such as azathioprine and biological agents such
as infliximab and adalimumab are also used, although these treatments are less commonly used owing to
risk factors. One of the most important medical treatments of UC involves corticosteroids such as
prednisone due to their immunosuppressive and short-term healing properties, but because their risks
outweigh their benefits, they are not used in long-term treatments [8,9].
Budesonide is considered a second-generation corticosteroid with improved clinical response in
patients with distal UC [10,11]. This drug has greater affinity for the intracytoplasmic glucocorticoid
receptors than other corticosteroids, which increases its anti-inflammatory power. However, the direct
administration of budesonide allows the drug to be absorbed in the proximal intestine and
metabolized in the liver, where more than 90% of the dose reaching the blood is transformed into two
inactive metabolites: 16a-hydroxyprednisolone and 6b-hydroxybudenoside [12]. These facts preclude
its arrival to the affected areas and give rise to adverse effects.
Several oral and rectal formulations such as those based on the use of multi-matrix system technology
have been explored to improve pharmacokinetic roles, but new studies directed towards the preparation
of more efficient formulations are being continuously published [13].
On the other hand, mesoporous silica materials (MSMs) have found a large number of potential
applications as drug delivery systems [14–19]. MSMs show unique properties such as large load
capacity, biocompatibility, high thermal stability, homogeneous porosity, inertness and tuneable
pore sizes. In addition, they can be prepared in the form of micro- or nanoparticles [20,21].
Moreover, it is possible to incorporate onto the external surface of MSMs functional organic and
biological groups which act as molecular gates, able to be opened or closed on command for
controlled-release applications. Based on this concept, a number of gated materials capable of
delivering their cargo upon application of physical, chemical or biochemical stimuli have been
described [22–25]. These controlled-release materials are promising candidates for a great number of
biological, pharmaceutical and medical applications [26–29]. For instance, the design of carriers able
to release certain drugs on the site of action to minimize secondary effects is a point of reference in
the treatment of different diseases.
As mentioned above, the development of new drug carriers for oral IBD treatment to decrease
adverse effects of drugs and enhance drug efficacy is a field of interest. In this scenario, formulations
for targeting the colon based on pH-responsive polymers, pressure-responsive systems, osmotic-
controlled and bio-adhesive materials, time-dependent formulations, prodrugs activated with enzymes
or drugs coated with enzyme-sensitive polymers have been reported [30–32]. In particular, the use of
enzymes produced by colon microbiota (azoreductase, ß-galactosidase, nitroreductase, etc.) as triggers
for drug release targeting is appealing [33]. However, although MSMs capped with different groups
have been reported to deliver their cargo by enzyme degradation [34], the use of such systems for the
specific delivery of drugs (such as budesonide) in the colon for the treatment of IBD has been barely
explored [35,36].
Following our interest in the use of gated mesoporous silica materials for controlled-release
applications, we have recently reported the synthesis of magnetic mesoporous silica microparticles,
loaded with a dye and capped with an azo derivative bearing a carbamate linkage, for the release





Scheme 1. Representation of micrometric silica mesoporous support loaded with safranin O (M-Saf ) or budesonide (M-Bud) and




3release at neutral pH although a sustained payload release was observed at acidic pH (2.0 and 4.5),
ascribable to the hydrolysis of the carbamate bond. Herein we describe the synthesis of simple
mesoporous silica microparticles loaded with a dye (safranin O) or with a drug (budesonide), and
capped with a bulky azo derivative, for the controlled release of the dye/drug in the colon,
triggered by the azoreductases produced by colon microbiota [38]. The azo derivative molecular
gate has been attached to the surface of the microparticles through a urea linkage, which is more
resistant towards acidic hydrolysis. We found that the presence of the bulky azoderivative on the
external surface of M-Saf (loaded with safranin O) and M-Bud (loaded with budesonide) inhibited
cargo delivery, yet both solids were able to deliver their cargo in the presence of a reducing agent
(sodium dithionite) (scheme 1) and to some extent at acidic pH (1.2). Moreover, preliminary in vivo
experiments have been carried out with mice which suggest that the material is able to release the
dye in the colon.2. Material and methods
2.1. General methods
Nuclear magnetic resonance (NMR), mass spectrometry, powder X-ray diffraction (PXRD), thermo-
gravimetric analysis (TGA), transmission electronic microscopy (TEM), N2 adsorption–desorption,




4chromatography (HPLC) techniques were employed to characterize the synthesized materials.
1H and
13C NMR spectra were acquired with a Bruker DRX500 spectrometer. High-resolution mass spectra
(HRMS) were recorded in the positive ion mode on an AB SCIEX TripleTOFTM 5600 liquid
chromatography/mass spectrometry spectrometer. The PXRD measurements were performed with a
Bruker D5005 diffractometer by using CuKa radiation. The TGA were carried out on a TG-DTA Pyris
Diamond by using an oxidant atmosphere (air 80 ml min–1) with a heating programme consisting of
heating steps at 58C per minute from 393 to 1273 K and an isothermal heating step at this
temperature for 30 min. The TEM images were obtained with a 100 kV JEM-1010 (JEOL). Grain size
distribution was determined by using a Malvern Mastersizer 2000 instrument equipped with a small-
volume sample dispersion unit. Water was the dispersion medium used. Each sample was measured
in triplicate, accumulating light scatter data for 10 s (in each measurement as well as in the
background). To facilitate particle dispersion, samples were sonicated during 2 min at 15 W in
successive treatments until stabilization of the particle size distribution. The N2 adsorption–
desorption were recorded with a Micrometrics ASAP2010 automated sorption analyser. Samples
were degassed at 1208C in vacuum overnight. Specific surface areas were calculated from the
absorption data in the low-pressure range by using the Brunauer–Ummett–Teller (BET) model. Pore
size was determined following the Barrett–Joyner–Halenda (BJH) method. The UV/Vis absorption
spectra were recorded in a 1 cm path length quartz cuvette with a Shimadzu UV-2101PC
spectrophotometer. Fluorescent spectroscopy studies were carried out with a Varian Cary Eclipse
fluorescent spectrophotometer. The HPLC analysis was carried out on a Teknokromaw Brisa LC2 C18
analytical column (5 mm, 150 mm  0.46 mm) connected to a HPLC (model Flexar Solvent Manager)
system (Perkin-Elmer) consisting of a Flexar binary LC pump (Flexar/291N1120202F), diode detector
UV (Flexar/292N1111504F) and 20 ml injection loop.
2.2. Chemicals
The chemicals tetraethyl orthosilicate (TEOS), n-cetyltrimethylammonium bromide (CTAB), sodium
hydroxide (NaOH), safranin O, budesonide, dichloromethane, 3-(triethoxysilyl)propyl isocyanate,
acetonitrile, hydrochloric acid, 4-nitroaniline, sodium nitrite (NaNO2), N-phenyldiethanolamine,
p-toluenesulfonyl chloride, pyridine, tetrahydrofuran (THF), methanol (MeOH) HPLC grade, sodium
sulfide nonahydrate (Na2S.9H2O) were obtained from Aldrich. n-hexane and ethyl acetate were
purchased from Scharlau. Sodium carbonate (Na2CO3), magnesium sulfate (MgSO4) and ammonium
chloride (NH4Cl) were purchased from VWR.
2.3. Synthesis of 3
N-phenyldiethanolamine (2) (4 g, 22.1 mmol) was dissolved in pyridine (40 ml) under argon atmosphere;
then p-toluenesulfonyl chloride (12.6 g, 66.3 mmol) was added. The reaction mixture was stirred in an ice
bath for 5 h. Water was added (150 ml), after which a white solid precipitate appeared. The crude
reaction was vacuum-filtered and washed with cold MeOH (15 ml), and dried for 48 h to give
pure 3 as a white solid (9.94 g, 92%). 1H NMR (300 MHz, CDCl3): d 7.71 (d, J ¼ 9.0 Hz, 4H), 7.28
(d, J ¼ 9.0 Hz, 4H), 7.13 (dd, J ¼ 8.8, 7.3 Hz, 2H), 6.70 (t, J ¼ 9.0 Hz, 1H), 6.43 (d, J ¼ 9.0 Hz, 2H), 4.09
(t, J ¼ 6.0 Hz, 4H), 3.55 (t, J ¼ 6.0 Hz, 4H), 2.42 (s, 6H) ppm.
2.4. Synthesis of 5
Sodium hydride (198 mg, 5 mmol) was dissolved in dry THF (20 ml) and then the flask was purged
several times with argon to remove oxygen and water from the atmosphere of the reaction. DL-1,2-
Isopropylideneglycerol (4) (560 ml, 4.5 mmol) was gradually added at room temperature. After this
addition, the crude reaction was stirred for 1 h at 408C. Compound 3 (1 g, 2.0 mmol) was dissolved
in anhydrous THF (15 ml) and then added dropwise to the crude reaction using a compensated
addition funnel. After this addition, the crude reaction was heated at reflux for 24 h. The final
brown crude was neutralized with ammonium chloride 10% solution (30 ml) and the organic
product was extracted with dichloromethane. Organic layers were dried with anhydrous MgSO4
and filtered off, and the solvent was removed under vacuum. Product 5 was purified by silica gel
column chromatography and hexane/ethyl acetate (8 : 2 v/v), as a brown oil (560 mg, 68%). 1H
NMR (300 MHz, CDCl3) d 7.20 (dd, J ¼ 8.9, 7.2 Hz, 2H), 6.75–6.62 (m, 3H), 4.29–4.21 (m, 2H), 4.03
(dd, J ¼ 8.2, 6.4 Hz, 2H), 3.73–3.43 (m, 14H), d 1.41 (s, 6H), 1.36 (s, 6H) ppm.
rsos.royalsocietypublishing.org
R.Soc.o
52.5. Synthesis of 7
4-Nitroaniline (6) (170 mg, 1.23 mmol) was dissolved in a mixture of concentrated hydrochloric acid
(0.31 ml) and H2O (2.5 ml). The resultant solution was cooled in an ice bath to 08C and stirred, as
sodium nitrite (103 mg, 1.5 mmol) in water (0.7 ml) was rapidly added. The crude reaction was stirred
at 08C until a clear solution was formed. This solution was added to a solution of compound 5
(500 mg, 1.23 mmol) in H2O (3.6 ml) and concentrated hydrochloric acid (0.2 ml) while maintaining
the temperature at below 08C. The reaction was stirred at 0–58C for 5 h. The final dark red product
was neutralized with a saturated sodium carbonate solution. The red solid was filtered and washed
with cold H2O. Product 7 was purified by silica gel column chromatography using ethyl acetate/
methanol (9 : 1 v/v) as the eluent, to yield a red solid (353 mg, 60%). 1H NMR (500 MHz, MeOD-d4) d
8.35 (d, J ¼ 9.0 Hz, 2H), 7.94 (d, J ¼ 9.0 Hz, 2H), 7.87 (d, J ¼ 9.0 Hz, 2H), 6.93 (d, J ¼ 9.0 Hz, 2H),
3.79–3.71 (m, 10H), 3.60–3.46 (m, 8H) ppm. 13C NMR (125 MHz, MeOD-d4) d 158.3, 153.6, 148.8,
145.0, 127.2, 125.7, 123.6, 112.9, 73.8, 72.3, 70.1, 64. 5, 52.2 ppm. pen
sci.5:1808732.6. Synthesis of 8
Compound 7 (300 mg, 0.63 mmol) was dissolved in methanol (25 ml), and the solution was heated until
reflux. The reducing agent was prepared as follows: sodium sulfide nonahydrate (Na2S.9H2O) (333 mg,
1.39 mmol) was dissolved in the minimum amount of water and sodium carbonate (107 mg, 1.01 mmol)
was added under stirring. This solution was added to the previous one. The resulting solution was
stirred at reflux for 2 h. The reaction mixture was poured over ice water. The organic product was
extracted with ethyl acetate. Organic layers were dried with anhydrous Na2SO4 and filtered off, and
the solvent was removed under vacuum to give pure 8 as a yellow solid (247 mg, 87%). 1H NMR
(500 MHz, MeOD-d4) d 7.69 (d, J ¼ 9.0 Hz, 2H), 7.61 (d, J ¼ 9.0 Hz, 2H), 6.85 (d, J ¼ 19.0 Hz, 2H), 6.74
(d, J ¼ 9.0 Hz, 2H), 3.78–3.74 (m, 2H), 3.71 (s, 8H), 3.60–3.47 (m, 8H). 13C NMR (125 MHz, MeOD-d4)
d 151.9, 151.1, 146.2, 144.9, 125.1, 125.0, 115.5, 112.8, 73.7, 72.3, 70.1, 64.5, 52.1 ppm. HRMS: MHþ
found: 449.2395, C22H32HN4O6 required 449.2403.2.7. Synthesis of 1
Compound 8 (200 mg, 0.44 mmol) was dissolved in dry THF (20 ml) under argon atmosphere and the
solution was heated at 408C. 3-(Triethoxysilyl)propyl isocyanate (117 ml, 0.47 mmol) was added under
stirring. The resultant solution was stirred at reflux for 72 h. The solvent was removed under vacuum
to give molecular gate 1 as an orange solid (260 mg). The crude product, which also contained about
30% of the starting amine 8 was used without further purification. 1H NMR (500 MHz, DMSO-d6) d
8.71 (s, 1H), 7.71–7.67 (m, 4H), 7.52 (d, J ¼ 10.0 Hz, 2H), 6.84 (d, J ¼ 10.0 Hz, 2H), 6.26 (t, J ¼ 5.5 Hz,
1H), 4.64–4.62 (m, 2H), 4,48 (t, J ¼ 5.8 Hz, 2H), 3.78–3.74 (m, 10H), 3.62–3.57 (m, 10H), 3.47–3.42
(m, 4H), 3.09–3.06 (m, 2H), 1.51–1.48 (m, 2H), 1.15 (t, J ¼ 7.0 Hz, 9H), 0.59–0.55 (m, 2H). 13C NMR
(125 MHz, DMSO-d6) d 154.87, 146.62, 142.53, 142.28, 131.84, 124.29, 122.78, 117.49, 111.34, 72.57,
70.57, 68.17, 63.04, 57.71, 50.36, 41.78, 23.28, 18.22, 7.26.2.8. Synthesis of mesoporous MCM-41 microparticles
The MCM-41 mesoporous microparticles were synthesized by the following procedure: triethanolamine
(TEAH3) (25.06 g, 168 mmol) was stirred at room temperature for 5 min. Then, NaOH (12 mmol) in
deionized water (2 ml) was added. The reaction mixture was heated at 1208C for 20 min. Next, the
solution temperature was adjusted to 708C. TEOS (10.6 ml, 45 mmol) was then added and was heated
to 1208C for 1 h. Then, the solution temperature was adjusted to 1188C and CTAB (4.68 g) was slowly
added. Next, the reaction mixture was cooled to 708C and deionized H2O (80 ml) was added with
vigorous stirring. After a few minutes, a white suspension resulted. This mixture was aged at room
temperature overnight. The resulting powder was collected by filtration and washed with water.
Finally, the solid was dried at 708C (MCM-41 as-synthesized). To prepare the final porous material
(MCM-41), the as-synthesized solid was calcined at 5508C using oxidant atmosphere for 5 h in order




62.9. Synthesis of M-Saf
In a typical synthesis, 1 g of MCM-41 mesoporous microparticles and the dye safranin O (500 mg) were
suspended in dry acetonitrile (30 ml) under inert atmosphere. The mixture was then stirred for 24 h at
room temperature to achieve maximum loading in the MCM-41 scaffolding pores. Next, the solid
was filtered off and washed. The solid was resuspendered in dry THF (25 ml). Compound 1 (1 g,
1.44 mmol) was dissolved in anhydrous THF (25 ml) and was added to MCM-41 material loaded
with safranin O. Excess safranin O was also added to the mixture to saturate the solution with dye,
thus preventing the dye from leaving the inlets of the MCM-41 pores. The mixture was stirred
for overnight at room temperature in an argon atmosphere. The solid was isolated by filtration and
thoroughly washed with THF, H2O until a colourless solution was obtained; then it was dried at 408C
for 12 h to yield M-Saf as a dark red-orange solid.
2.10. Synthesis of M-Bud
In a typical synthesis, 500 mg of MCM-41 and budesonide (500 mg, 1.16 mmol) were suspended in dry
acetonitrile (30 ml) under an inert atmosphere. The mixture was then stirred for 24 h at 608C to achieve
maximum loading in the MCM-41 scaffolding pores. Next, compound 1 (500 mg, 0.72 mmol) was added
in anhydrous THF (25 ml). The mixture was stirred overnight at room temperature. The solid was
isolated by filtration and thoroughly washed with THF, H2O until a colourless solution was obtained;
then it was dried at 408C for 12 h to yield M-Bud as a yellow solid.
2.11. In vivo release studies
The studies reported here adhere to the Principles of Laboratory Animal Care and were approved by the
institutional ethics committee of the Conselleria de Agricultura, Medio Ambiente, Cambio Clima´tico
y Desarrollo Rural (Generalitat Valenciana), according to 2016/VSC/PEA/00158. In a typical
experiment, 10 mg of M-Saf was suspended in water (200 ml). The mixture was administered to a
mouse by oral gavage by using a cannula provided with a rounded tip. The mouse, with free access
to water and food, was observed during 4 h, showing a normal behaviour. The mouse was
euthanized with an overdose of anaesthesia (dolethalw) and then the abdomen was opened and the
digestive system was removed. The digestive system was dissected to locate the microparticles
through it. The M-Saf was observed to pass freely without causing any ulcer or absorption in the
other tissues. An appreciable amount of closed material was still present in the stomach; in addition,
the microparticles located along the small intestine remained also closed. The material isolated in
each section was evaluated using sodium dithionite, and the safranin O delivered was followed by
fluorescence spectrometry (figure 5; electronic supplementary material, figure S19). In addition,
another mouse was studied during 24 h after oral administration of M-Saf. After 24 h the mouse
was euthanized in similar conditions and the digestive system was dissected to locate the
microparticles through it. After this time, no appreciable amounts of closed material were present in
the stomach, intestine or colon, and the corresponding release studies using Na2S2O4 did not show
the presence of safranin O in the extracted solutions. In addition, the stool was also evaluated. The
stool was homogenized and suspended in water (5 ml) during 24 h at room temperature. The
mixture was centrifuged and the supernatant was separated. The solid was suspended again in
water (5 ml) and safranin O release was evaluated using sodium dithionite (electronic
supplementary material, figure S20).3. Results and discussion
3.1. Synthesis and characterization of the gated microparticles
In designing gated supports for a certain application, three issues need to be defined: (i) the capping
ensemble used to inhibit cargo delivery, (ii) the trigger that would induce payload release, and (iii) the
support containing the cargo [39–41]. In this work, mesoporous silica in the form of microparticles
was selected as the scaffold. We selected a standard MCM-41 material instead of other related
samples such as uniform mesoporous silica spheres, owing to the larger size of the MCM-41










7targeting to ensure the arrival of the gated material to the area to be treated, avoiding the passage of the
material to the bloodstream through the intestine [42]. The selected material contains uniform mesopores
in the 2–3 nm range that allow cargo loading; however, the presence of silanol groups on the surface
allows anchoring of the capping system through the well-known chemistry of alkoxysilanes [43]. As
the capping ensemble a bulky azo-derivative was designed (see molecule 1 in scheme 2), which is
expected to be opened by azoreductases produced by the colon microbiota.
The synthesis of 1 is shown in scheme 2. In addition to the cleavable azo group, 1 was designed to
contain appended hydroxyl and ether moieties that were expected to be bulk enough to inhibit cargo
delivery and, at the same time, to allow water solubility of the residue obtained after the enzymatic
rupture of the azo group. Compound 1 also contains a trialcoxysilyl group connected to the azo
moiety through a urea spacer, which is resistant to enzymatic hydrolysis [44]. The synthetic sequence
followed for the preparation of 1 started with di-tosylation of N-phenyldiethanolamine (2), followed
by reaction of the di-tosylated derivative 3 with the sodium salt of DL-1,2-isopropylideneglycerol (4).
These reactions yielded the aniline derivative 5, which was further coupled with 4-nitroaniline (6)
by employing sodium nitrite to obtain the azonitro derivative 7. Reduction of the nitro group
using sodium sulfide gave the corresponding amino compound 8. Finally, reaction of 8 with
(3-isocyanatopropyl) triethoxysilane yielded 1.
Microparticulated mesoporous silica was prepared following well-known procedures by using TEOS,
which acts as an inorganic precursor, and CTAB, which serves as a structure-directing agent [45]. The
subsequent removal of the surfactant by calcination in air at high temperature yielded the starting
mesoporous inorganic support (MCM-41 calcined).
Two final materials, loaded with safranin O (M-Saf ) and budesonide (M-Bud), were prepared using
a two-step protocol. In the first step, the pores of the calcined mesoporous scaffold were loaded with
safranin O or budesonide by simply stirring a suspension of the microparticles in a solution of the
cargo in dry acetonitrile at room temperature (in the case of safranin O) or at 508C (for budesonide) in
an argon atmosphere for 24 h. In the second step, the external surface of the microparticles was
functionalized by reaction of the trialkoxysilane group in 1 with silanol moieties on the silica surface.
This procedure yielded the final loaded gated materials (i.e. M-Saf and M-Bud) as red-pink and
yellow solids, respectively.
The starting mesoporous silica scaffold and the final microparticles were characterized by following
standard procedures (see the electronic supplementary material for details). Figure 1 shows the PXRD
patterns of the microparticulated mesoporous silica as-synthesized and calcined, and the solids M-Saf
and M-Bud. Mesoporous silica microparticles as-synthesized (curve a) displayed four typical low-
angle reflections of a hexagonal-ordered matrix indexed at (100), (110), (200) and (210) Bragg peaks. In
curve b (calcined), a significant shift of the (100) peak in the PXRD and a broadening of the (100) and
(200) peaks were observed. These changes are in agreement with the condensation of silanols in the


































Figure 2. TEM images: (a) calcined MCM-41, (b) M-Saf and (c) M-Bud. Right: laser diffraction particle size distribution of




8calcination step. Curves (c) and (d) show the PXRD pattern of solids M-Saf and M-Bud. For these
materials, reflections (110) and (200) were partially lost owing to a reduction in contrast related to the
functionalization process and to the filling of mesoporous systems with safranin O (M-Saf ) or drug
budesonide (M-Bud). However, the intensity of the (100) peak in these patterns strongly indicates that
the mesoporous structure was preserved after the loading process and the additional functionalization
with azo derivative 1.
The presence of a mesoporous structure on the starting mesoporous material,M-Saf andM-Bud was
also confirmed by TEM (figure 2, left), where alternate black and white strips or spots (owing to the
organized mesopores) can be clearly observed. A lower-order degree is detected for M-Saf and M-Bud
Table 1. BET-specific surface values, pore volumes and pore sizes calculated from N2 adsorption–desorption isotherms for
selected materials.
SBET (m
2 g21) BJH porea,b (nm) total pore volumea (cm3 g21)
MCM-41 1193.4 2.56 0.99
M-Saf 820.4 2.47 0.52
M-Bud 761.2 2.53 0.54
aTotal pore volume according to the BJH model.
bPore size estimated by using the BJH model applied on the adsorption branch of the isotherm, for P/P0 , 0.6, which can be
associated to the surfactant-generated mesopores.
Table 2. Total organic matter and amount of cargo (in mg mg21 of solid) for M-Saf and M-Bud microparticles.






9when compared with the starting silica, according to PXRD data. In all cases, the particles have irregular
shapes, with a certain aggregation degree leading to grains of micrometric scale. Averaged grain sizes of
about 3.2 and 7.2 mm have been determined through laser diffraction (figure 2, right) for samples M-Saf
and M-Bud, respectively.
The N2 adsorption–desorption isotherms for calcined mesoporous microparticles and the gated
solids M-Saf and M-Bud were registered and are shown in the electronic supplementary material,
figure S9. Curve (a) corresponds to MCM-41 and showed the typical curve for these materials, with
an adsorption step at a P/P0 value between 0.1 and 0.3. This corresponds to a type IV isotherm,
which is typical of mesoporous materials. This first step is ascribed to nitrogen condensation in the
mesopore inlets. The pore diameter (2.56 nm) and pore volume (0.99 cm3 g21) were calculated using
the BJH model on the adsorption curve of the isotherm [46]. The absence of a hysteresis loop
indicated the cylindrical uniformity of mesopores. The total specific area was 1193.4 m2 g21,
calculated using the BET model [47]. In the solids M-Saf and M-Bud, the N2 adsorption–
desorption isotherms were characteristic of mesoporous systems with partially filled mesopores
(electronic supplementary material, figure S9, curves b and c). A lower N2 adsorbed volume and
surface area were determined when compared with the initial mesoporous material (electronic
supplementary material, figure S9, curve a). This reduction in the BET surface can be explained by
the presence of cargo in pores of M-Saf and M-Bud and the functionalization of the external
surface with the azo derivative 1. Table 1 shows a summary of the BET-specific surface values, pore
volume and pore sizes calculated from the N2 adsorption–desorption isotherms for all the prepared
solids. After loading and functionalization, a slight reduction in the accessible mesopore size is
observed. The total organic content for M-Saf and M-Bud solids was determined by thermo-
gravimetric analysis and the amount of cargo was determined by elemental analysis and UV-vis
spectroscopy (M-Saf ) (table 2).3.2. Cargo release studies
SolidsM-Saf andM-Bud contain safranin O and budesonide, respectively, and are functionalized on the
outer surface with 1. The presence of this bulky molecule on the external surface of the solids was
expected to inhibit the release of the cargo entrapped inside the pores. Cargo release from M-Saf was
tested at different pH, simulating the values of gastric juices (1.2), the transition from stomach to
intestines (4.5) and that found in the intestine (6.8). In addition, the response of M-Saf was also tested
in the presence of a reducing agent (sodium dithionite, which mimics azoreductase enzymes present
in the colon environment) and of the enzyme nitrate reductase (which is present in the intestinal
microflora).
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10Dye delivery from M-Saf was followed by UV-vis spectroscopy monitoring the safranin O band
centred at 520 nm (see the electronic supplementary material). In a typical experiment, M-Saf (5 mg)
was suspended in water (17 ml) at selected pH (6.8, 4.5 and 1.2) in the absence or in the presence of
excess sodium dithionite (3 mg). Aliquots were taken at scheduled times and filtered off in order to
eliminate the suspended microparticles, and the absorbances of the resulting solutions were measured
to determine the amount of safranin O released from M-Saf. The obtained release profiles are shown
in figure 3. In the absence of a reducing agent, and at neutral (6.8) or moderate acidic (4.5) pH,
negligible safranin O release from M-Saf microparticles was observed (maximum delivery of 3.7 and
6.3 mg mg21 solid at pH 6.8 and 4.5, respectively, after 24 h). However, when the pH was set at 1.2, a
moderate safranin O release was found (17 mg mg21 solid after 24 h). This delivery is ascribed to a
partial hydrolysis of the urea bonds in azo derivative 1 in the highly acidic environment in which the
release was carried out. On the other hand, an increased and marked delivery of safranin O from
M-Saf microparticles at the three tested pH values in the presence of sodium dithionite was observed
(figure 3). Nearly the same amount of safranin O at pH 6.8 and 4.5 was observed in the presence of
the reducing agent (about 32 mg mg21 solid after 24 h). The higher dye release was observed at pH
1.2 in the presence of sodium dithionite (38 mg mg21 solid, which corresponds to about 60% of dye
release, after 24 h). The observed delivery is ascribed to the reductive cleavage of the azo bond in
1 by dithionite, resulting in the opening of the pores and safranin O release to the medium [37]. This
cleavage was also confirmed by 1H-NMR experiments (see the electronic supplementary material,
figure S11). Finally, cargo release studies from M-Saf microparticles at neutral pH (7.5) in the
presence of nitrate reductase showed negligible safranin O release (data not shown).
Cargo release from M-Bud at neutral pH (not buffered) and in the absence or presence of sodium
dithionite was also tested. Budesonide release from M-Bud microparticles was followed by UV-vis by
monitoring the drug absorption band centred at 241 nm [48]. Aqueous suspensions of M-Bud showed
a marked absorption band at 463 nm that was ascribed to the azo derivative gate grafted onto the
outer surface of the microparticles (figure 4). The intensity of this visible band remained unchanged
with time, indicating tight pore closure and negligible budesonide release. However, in the presence
of sodium dithionite (1 mM), the absorbance at 463 nm disappeared with time and another band
corresponding to budesonide at 241 nm appeared (see again figure 4). The maximum intensity of the
241 nm band was reached 4 h after the addition of the reducing agent.
To determine the amount of budesonide released from M-Bud, HPLC studies were carried out. In a
typical experiment, M-Bud (5 mg) was suspended in water at neutral pH (20 ml) and then an excess of
sodium dithionite (3 mg) was added. After stirring at room temperature, aliquots were separated at
fixed times, centrifuged to remove the solid and analysed by HPLC [49]. These measurements showed
a release of 21.1 mg of budesonidemg21 solid after 5 min with a maximum drug delivery of




















M-Bud + 3 mg Na2S2O4 t 5¢
Figure 4. UV-vis spectrum of aqueous suspensions of M-Bud in the absence (blue) and in the presence of sodium dithionite (red)
after 4 h.
250 M-Saf in the stomach + Na2S2O4
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Figure 5. Safranin O emission band (excitation at 520 nm) from aqueous suspensions (1.5 ml) of M-Saf nanoparticles isolated from




113.3. In vivo release studies
Preliminary in vivo studies with solid M-Saf were carried out with mice in order to evaluate the in vivo
safranin O release along the entire gastrointestinal tract (GIT). In a typical experiment, M-Saf
microparticles (10 mg) were suspended in water (200 ml) and then administered to a mouse by oral
gavage. After 4 h of M-Saf administration, the mouse was euthanized and the digestive system was
extracted and dissected in order to ascertain the presence of microparticles along it. As a first
conclusion, M-Saf microparticles passed through the GIT without causing any ulcer. On the other hand,
appreciable amounts of microparticles were present in the stomach and in the small intestine. Then, the
microparticles isolated from the different sections of the GIT were suspended in an aqueous solution of
sodium dithionite in order to test the preservation of the capping azo derivative 1. In this regard, when
the microparticles isolated from the stomach and small intestine were suspended in water, a negligible
emission of safranin O at 550 nm (when excited at 520 nm) was observed (figure 5). On the other hand,
when the isolated solids were suspended in water containing the reducing agent, a remarkable emission
at 550 nm was found (figure 5). The obtained results suggested that capping azo derivative 1, attached
onto the external surface of M-Saf microparticles, retains its chemical integrity on passing through the
GIT during, at least, 4 h. The same experiment was repeated but this time the location and integrity of
the microparticles were tested after 24 h of M-Saf oral administration. After 24 h of the treatment, the
mouse was euthanized and the digestive system was studied as before. In this case, unappreciable
amounts of microparticles in the stomach and small intestine were observed. In addition, the
microparticles found in faeces did not contain the dye (see the electronic supplementary material),





In conclusion, capped silica microparticles loaded with the dye safranin O (M–Saf ) or the drug
budesonide (M–Bud) have been prepared and characterized. The capping unit in both materials is a
bulky azo derivative which could be broken under reducing conditions (such as those presented in
the colon mucosa). Delivery studies at different pH values were undertaken with M-Saf using
UV–vis spectroscopy. At neutral (6.8) or moderately acidic (4.5) pH, M-Saf showed very low safranin-
O release. At acidic pH (1.2), a moderate dye release was observed owing to the hydrolysis of the
urea bonds that linked the bulky azo derivative onto the external surface of the loaded support.
However, in the presence of sodium dithionite (as a mimic of azoreductase enzyme), a marked
safranin O release was observed even at neutral pH. This delivery is ascribed to the reductive
cleavage of the azo bond, leading to the opening of the pores and subsequent dye delivery. The
encapsulation and controlled release of the drug budesonide, used in the treatment of UC, has also
been demonstrated with solid M-Bud in the presence of sodium dithionite by UV and HPLC
measurements. Finally, some preliminary in vivo experiments carried out with mice seem to indicate
that M-Saf retains its chemical integrity in the stomach and the small intestine and it is able to release
the dye in the last part of GIT mucosa. We think that these gated microparticles are promising
materials for budesonide delivery in the oral treatment of UC.
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